Perspective Therapeutics Appoints GSK’s Maya Martinez-Davis to Board of Directors

Perspective Therapeutics, Inc. announced the appointment of Maya Martinez-Davis as an independent director to its Board of Directors, effective immediately. The addition of Martinez-Davis strengthens the Company’s leadership as it continues advancing its radiopharmaceutical pipeline targeting cancers across the body.

Lori Woods, Chairperson of Perspective, commented, "The Board and I are excited to welcome Maya and look forward to working with her as we continue to guide the Company towards building long-term shareholder value. Maya brings a phenomenal breadth of experiences, which we believe are highly complementary to the experience of our existing directors and Perspective's management team. We believe she will be a strong steward for shareholders in helping advance our clinical programs and deliver on our goal of helping cancer patients with limited treatment options."

Martinez-Davis currently serves as President of GSK’s U.S. Commercial business, where she oversees a diverse portfolio spanning specialty medicines, oncology, respiratory, and vaccines. Before joining GSK in 2019, she held leadership positions at Merck KGaA as President of biopharma Latin America and earlier as Head of Global Oncology. She also spent over a decade at Pfizer in senior roles across oncology, vaccines, and specialty portfolios.

"I am excited to join Perspective's Board at such a pivotal time in the rapidly evolving radiopharma field, and to help demonstrate the promise of alpha emitting radioisotopes in the treatment of cancers throughout the body. I look forward to sharing my insights and experience with the Perspective team, as the Company advances its three clinical-stage programs with potential to transform cancer treatment," said Ms. Martinez-Davis. 

In addition to her executive career, Martinez-Davis brings board-level experience, having previously served on the Board of Directors of Mirati Therapeutics until its acquisition by Bristol Myers Squibb in 2024. She holds a bachelor’s degree from Saint Louis University and a master’s in business leadership and marketing from the IE Business Institute in Madrid, Spain.

Thijs Spoor, Perspective's CEO, said, "I welcome the opportunity to work with Maya. Her commercial and clinical development experience in oncology will be a valuable resource for the Perspective team. We are at an exciting time in the Company's history, as we are excited by the potential of our cutting-edge science to produce innovative new medicines that could improve patients' lives."